Skip to main content

Molecular Partners to Host Oncology Day (Virtual)

Written by Customer Service on . Posted in Public Companies.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Senior Management and invited guests will host a virtual Oncology R&D Day.

Updates from today’s talk will include:

  • Overview of clinical strategy and corporate outlook 2022 and beyond
    • Patrick Amstutz, PhD, CEO of Molecular Partners
  • Update and status of Abicipar- investigational anti-VEGF for the treatment of nAMD and DME
    • Michael Stumpp, PhD, COO of Molecular Partners
  • DARPin applications and technological advancements
    • Daniel Steiner, PhD, SVP Research
  • Multispecific immune cell engagers, Targeting CD40 and 4-1bb in combination with Fibroblast Activation Protein (FAP)
    • Nicolas Leupin, MD, PhD, CMO of Molecular Partners
  • AML: Emerging treatment landscape and the targeting of leukemic stem cells
    • Professors Adrian Ochsenbein, MD, and Carsten Riether, PhD – Inselspital, Bern University Hospital
  • MP0533, a trispecific t-cell engager for the treatment of AML
    • Anne Goubier, DVM, PhD, VP Biology at Molecular Partners

“We are happy to share and celebrate the great advancements our team has achieved in the last year, and even more so in the last few weeks, which have been especially busy,” said Patrick Amstutz, CEO of Molecular Partners. “Even as COVID-19 continues to occupy our lives, and remains a focus for the company, our team still managed to advance our internal oncology programs and initiate a new DARPin-RLT program in collaboration with Novartis. We will discuss today the progress made, the strategy moving forward, and the upcoming milestones in our oncology pipeline.”

Following the prepared remarks both management and guest speakers will be available for a question-and-answer session. A copy of the presentation and a link to the live webcast of the Oncology Day will be available in the Investors section of the Company’s website at www.molecularpartners.com. An archived webcast recording of the event will be available on the website following the presentation.

Call Details:
Date: December 15, 2021
Time: 8:30 am ET (2:30 pm CET)
Registration: Register here
Dial-in: Participant Toll Free Dial-In Number: (833) 488-0261
 Participant International Dial-In Number: (909) 222-1963

About Molecular Partners AG 
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter – @MolecularPrtnrs

CONTACT: For further details, please contact:
Seth Lewis
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Shai Biran, Ph.D.
shai.biran@molecularpartners.com
Tel: +1 978 254 6286

Thomas Schneckenburger, European IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 79 407 9952

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.